Clinical Trials Logo

Clinical Trial Summary

A Two-Part, Open-Label, Crossover, Bioavailability Study Comparing Tablet and Oral Solution Formulations of BLD-0409 in Healthy Volunteers


Clinical Trial Description

The study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of two oral formulations of BLD-0409, tablet and solution, in healthy volunteers (HV). The study consists of two parts: Part 1: A randomized, open-label, 3-period, 6-sequence, complete crossover study with at least 3-day washout between treatment periods comparing oral solution formulation to tablet formulation. Part 2: A randomized, open-label, 4-period, 4-sequence, complete crossover study with at least 3-day washout between treatment periods evaluating single ascending doses of tablet formulation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04814472
Study type Interventional
Source Blade Therapeutics
Contact
Status Completed
Phase Phase 1
Start date May 16, 2021
Completion date November 3, 2021

See also
  Status Clinical Trial Phase
Completed NCT02052349 - Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects Phase 1
Completed NCT01911741 - A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects Phase 1
Active, not recruiting NCT03154840 - Relative Bioavailability Among Different Eutropin Formulations Phase 1
Completed NCT03934333 - A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS) Phase 1
Not yet recruiting NCT06025318 - An Evaluation of the Effect of Food on the PK of a Novel PanCytoVirâ„¢ Suspension (100mg/ml), in Healthy, Adult Volunteers Phase 1
Not yet recruiting NCT06025344 - A Relative Bioavailability Study With a Novel PanCytoVirâ„¢ Oral Suspension (100 mg/ml) Phase 1
Completed NCT04686669 - A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations Phase 1
Completed NCT03483259 - To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers Phase 1
Completed NCT05296382 - Bioavailability of Tebipenem (SPR994) Crushed Tablet Phase 1